Skip to main content
Top
Published in: Diabetologia 1/2017

Open Access 01-01-2017 | Position Statement

Glucose concentrations of less than 3.0 mmol/l (54 mg/dl) should be reported in clinical trials: a joint position statement of the American Diabetes Association and the Europian Association for the Study of Diabetes

Author: The International Hypoglycaemia Study Group

Published in: Diabetologia | Issue 1/2017

Login to get access

Excerpt

The International Hypoglycaemia Study Group recommends that the frequency of detection of a glucose concentration <3.0 mmol/l (<54 mg/dl), which it considers to be clinically significant biochemical hypoglycaemia, be included in reports of clinical trials of glucose-lowering drugs evaluated for the treatment of diabetes mellitus. …
Appendix
Available only for authorised users
Literature
1.
go back to reference Amiel SA, Sherwin RS, Simonson DC, Tamborlane WV (1988) Effect of intensive insulin therapy on glycemic thresholds for counterregulatory hormone release. Diabetes 37:901–907CrossRefPubMed Amiel SA, Sherwin RS, Simonson DC, Tamborlane WV (1988) Effect of intensive insulin therapy on glycemic thresholds for counterregulatory hormone release. Diabetes 37:901–907CrossRefPubMed
2.
go back to reference Boyle PJ, Schwartz NS, Shah SD, Clutter WE, Cryer PE (1988) Plasma glucose concentrations at the onset of hypoglycemic symptoms in patients with poorly controlled diabetes and in non-diabetics. N Engl J Med 318:1487–1492CrossRefPubMed Boyle PJ, Schwartz NS, Shah SD, Clutter WE, Cryer PE (1988) Plasma glucose concentrations at the onset of hypoglycemic symptoms in patients with poorly controlled diabetes and in non-diabetics. N Engl J Med 318:1487–1492CrossRefPubMed
3.
go back to reference Heller SR, Cryer PE (1991) Reduced neuroendocrine and symptomatic responses to subsequent hypoglycemia after 1 episode of hypoglycemia in nondiabetic humans. Diabetes 40:223–226CrossRefPubMed Heller SR, Cryer PE (1991) Reduced neuroendocrine and symptomatic responses to subsequent hypoglycemia after 1 episode of hypoglycemia in nondiabetic humans. Diabetes 40:223–226CrossRefPubMed
4.
go back to reference Dagogo-Jack S, Craft S, Cryer PE (1993) Hypoglycemia-associated autonomic failure in insulin-dependent diabetes mellitus: recent antecedent hypoglycemia reduces autonomic responses to, symptoms of, and defense against subsequent hypoglycemia. J Clin Invest 91:819–828CrossRefPubMedPubMedCentral Dagogo-Jack S, Craft S, Cryer PE (1993) Hypoglycemia-associated autonomic failure in insulin-dependent diabetes mellitus: recent antecedent hypoglycemia reduces autonomic responses to, symptoms of, and defense against subsequent hypoglycemia. J Clin Invest 91:819–828CrossRefPubMedPubMedCentral
5.
go back to reference Cryer PE (2013) Mechanisms of hypoglycemia-associated autonomic failure in diabetes. N Engl J Med 369:362–372CrossRefPubMed Cryer PE (2013) Mechanisms of hypoglycemia-associated autonomic failure in diabetes. N Engl J Med 369:362–372CrossRefPubMed
6.
go back to reference Workgroup on Hypoglycemia, American Diabetes Association (2005) Defining and reporting hypoglycemia in diabetes: a report from the American Diabetes Association Workgroup on Hypoglycemia. Diabetes Care 28:1245–1249 Workgroup on Hypoglycemia, American Diabetes Association (2005) Defining and reporting hypoglycemia in diabetes: a report from the American Diabetes Association Workgroup on Hypoglycemia. Diabetes Care 28:1245–1249
7.
go back to reference Seaquist ER, Anderson J, Childs B et al (2013) Hypoglycemia and diabetes: a report of a workgroup of the American Diabetes Association and the Endocrine Society. Diabetes Care 36:1384–1395CrossRefPubMedPubMedCentral Seaquist ER, Anderson J, Childs B et al (2013) Hypoglycemia and diabetes: a report of a workgroup of the American Diabetes Association and the Endocrine Society. Diabetes Care 36:1384–1395CrossRefPubMedPubMedCentral
8.
go back to reference Cryer PE (2001) The prevention and correction of hypoglycemia. In: Jefferson LS, Cherrington AD (eds) Handbook of physiology, section 7, volume II, The Endocrine Pancreas and Regulation of Metabolism. Oxford University Press, New York, pp 1057–1092 Cryer PE (2001) The prevention and correction of hypoglycemia. In: Jefferson LS, Cherrington AD (eds) Handbook of physiology, section 7, volume II, The Endocrine Pancreas and Regulation of Metabolism. Oxford University Press, New York, pp 1057–1092
9.
go back to reference Cryer PE (2016) Hypoglycemia in diabetes, 3rd edition. American Diabetes Association, Alexandria, p 33 Cryer PE (2016) Hypoglycemia in diabetes, 3rd edition. American Diabetes Association, Alexandria, p 33
10.
go back to reference Frier BM, Heller SR, McCrimmon RJ (eds) (2014) Hypoglycaemia in clinical diabetes, 3rd edn. John Wiley & Sons, Chichester, p 49 Frier BM, Heller SR, McCrimmon RJ (eds) (2014) Hypoglycaemia in clinical diabetes, 3rd edn. John Wiley & Sons, Chichester, p 49
11.
go back to reference Heller SR, Macdonald IA (1996) The measurement of cognitive function during acute hypoglycaemia: experimental limitations and their effect on the study of hypoglycaemia unawareness. Diabet Med 13:607–615CrossRefPubMed Heller SR, Macdonald IA (1996) The measurement of cognitive function during acute hypoglycaemia: experimental limitations and their effect on the study of hypoglycaemia unawareness. Diabet Med 13:607–615CrossRefPubMed
12.
go back to reference Choudhary P, Lonnen K, Emery CJ et al (2009) Comparing hormonal and symptomatic responses to experimental hypoglycaemia in insulin- and sulphonylurea-treated type 2 diabetes. Diabet Med 26:665–672CrossRefPubMed Choudhary P, Lonnen K, Emery CJ et al (2009) Comparing hormonal and symptomatic responses to experimental hypoglycaemia in insulin- and sulphonylurea-treated type 2 diabetes. Diabet Med 26:665–672CrossRefPubMed
13.
go back to reference Matyka K, Evans M, Lomas J, Cranston L, Macdonald I, Amiel SA (1997) Altered hierarchy of protective responses against severe hypoglycemia in normal aging in healthy men. Diabetes Care 20:135–141CrossRefPubMed Matyka K, Evans M, Lomas J, Cranston L, Macdonald I, Amiel SA (1997) Altered hierarchy of protective responses against severe hypoglycemia in normal aging in healthy men. Diabetes Care 20:135–141CrossRefPubMed
14.
go back to reference Gonder-Frederick LA, Zrebiec JF, Bauchowitz AU et al (2009) Cognitive function is disrupted by both hypo- and hyperglycemia in school-aged children with type 1 diabetes: a field study. Diabetes Care 32:1001–1006CrossRefPubMedPubMedCentral Gonder-Frederick LA, Zrebiec JF, Bauchowitz AU et al (2009) Cognitive function is disrupted by both hypo- and hyperglycemia in school-aged children with type 1 diabetes: a field study. Diabetes Care 32:1001–1006CrossRefPubMedPubMedCentral
15.
go back to reference Fanelli CG, Epifano L, Rambotti AM et al (1993) Meticulous prevention of hypoglycemia normalizes the glycemic thresholds and magnitude of most neuroendocrine responses to, symptoms of, and cognitive function during hypoglycemia in intensively treated patients with short-term IDDM. Diabetes 42:1683–1689CrossRefPubMed Fanelli CG, Epifano L, Rambotti AM et al (1993) Meticulous prevention of hypoglycemia normalizes the glycemic thresholds and magnitude of most neuroendocrine responses to, symptoms of, and cognitive function during hypoglycemia in intensively treated patients with short-term IDDM. Diabetes 42:1683–1689CrossRefPubMed
16.
go back to reference Fanelli C, Pampanelli S, Epifano L et al (1994) Long-term recovery from unawareness, deficient counterregulation and lack of cognitive dysfunction during hypoglycaemia following institution of rational, intensive insulin therapy in IDDM. Diabetologia 37:1265–1276 Fanelli C, Pampanelli S, Epifano L et al (1994) Long-term recovery from unawareness, deficient counterregulation and lack of cognitive dysfunction during hypoglycaemia following institution of rational, intensive insulin therapy in IDDM. Diabetologia 37:1265–1276
17.
go back to reference Cranston I, Lomas J, Maran A, Macdonald I, Amiel SA (1994) Restoration of hypoglycemia awareness in patients with long-duration insulin-dependent diabetes. Lancet 344:283–287CrossRefPubMed Cranston I, Lomas J, Maran A, Macdonald I, Amiel SA (1994) Restoration of hypoglycemia awareness in patients with long-duration insulin-dependent diabetes. Lancet 344:283–287CrossRefPubMed
18.
go back to reference Dagogo-Jack S, Rattarasarn C, Cryer PE (1994) Reversal of hypoglycemia unawareness, but not defective glucose counterregulation, in IDDM. Diabetes 43:1426–1434CrossRefPubMed Dagogo-Jack S, Rattarasarn C, Cryer PE (1994) Reversal of hypoglycemia unawareness, but not defective glucose counterregulation, in IDDM. Diabetes 43:1426–1434CrossRefPubMed
19.
go back to reference Chow E, Bernjak A, Williams S et al (2014) Risk of cardiac arrhythmias during hypoglycemia in patients with type 2 diabetes and cardiovascular risk. Diabetes 63:1738–1747CrossRefPubMed Chow E, Bernjak A, Williams S et al (2014) Risk of cardiac arrhythmias during hypoglycemia in patients with type 2 diabetes and cardiovascular risk. Diabetes 63:1738–1747CrossRefPubMed
20.
go back to reference Pistrosch F, Ganfacz X, Bornstein SR, Birkenfeld AL, Henkel E, Hanefeld M (2015) Risk of and risk factors for hypoglycemia and associated arrhythmias in patients with type 2 diabetes and cardiovascular disease; a cohort study under real world conditions. Acta Diabetol 52:889–895CrossRefPubMed Pistrosch F, Ganfacz X, Bornstein SR, Birkenfeld AL, Henkel E, Hanefeld M (2015) Risk of and risk factors for hypoglycemia and associated arrhythmias in patients with type 2 diabetes and cardiovascular disease; a cohort study under real world conditions. Acta Diabetol 52:889–895CrossRefPubMed
21.
go back to reference Bonds DE, Miller ME, Bergenstal RM et al (2010) The association between symptomatic, severe hypoglycaemia and mortality in type 2 diabetes: retrospective epidemiological analysis of the ACCORD study. BMJ 340:b4909CrossRefPubMedPubMedCentral Bonds DE, Miller ME, Bergenstal RM et al (2010) The association between symptomatic, severe hypoglycaemia and mortality in type 2 diabetes: retrospective epidemiological analysis of the ACCORD study. BMJ 340:b4909CrossRefPubMedPubMedCentral
22.
go back to reference Outcomes Reduction with an Initial Glargine Intervention (ORIGIN) Investigators (2013) Does hypoglycemia increase the risk of cardiovascular events? A report from the ORIGIN trial. Eur Heart J 34:3137–3144 Outcomes Reduction with an Initial Glargine Intervention (ORIGIN) Investigators (2013) Does hypoglycemia increase the risk of cardiovascular events? A report from the ORIGIN trial. Eur Heart J 34:3137–3144
23.
go back to reference Normoglycemia in Intensive Care Evaluation—Survival Using Glucose Algorithm Regulation (NICE-SUGAR) Investigators (2012) Hypoglycemia and risk of death in critically ill patients. N Engl J Med 367:1108–1118CrossRef Normoglycemia in Intensive Care Evaluation—Survival Using Glucose Algorithm Regulation (NICE-SUGAR) Investigators (2012) Hypoglycemia and risk of death in critically ill patients. N Engl J Med 367:1108–1118CrossRef
24.
go back to reference International Hypoglycemia Study Group (2015) Minimizing hypoglycemia in diabetes. Diabetes Care 38:1583–1591CrossRef International Hypoglycemia Study Group (2015) Minimizing hypoglycemia in diabetes. Diabetes Care 38:1583–1591CrossRef
Metadata
Title
Glucose concentrations of less than 3.0 mmol/l (54 mg/dl) should be reported in clinical trials: a joint position statement of the American Diabetes Association and the Europian Association for the Study of Diabetes
Author
The International Hypoglycaemia Study Group
Publication date
01-01-2017
Publisher
Springer Berlin Heidelberg
Published in
Diabetologia / Issue 1/2017
Print ISSN: 0012-186X
Electronic ISSN: 1432-0428
DOI
https://doi.org/10.1007/s00125-016-4146-6

Other articles of this Issue 1/2017

Diabetologia 1/2017 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.